Research summary, original research, 2015

Surgeon Radiation Dose During Complex Endovascular Procedures

Kirkwood ML, Guild JB, Arbique GM, Anderson JA, Valentine RJ, Timaran C. Journal of vascular surgery. 2015

Read the original paper

In plain language

In vascular surgeons doing endovascular procedures, measured dose was highest for fenestrated aneurysm repair and at the main operator and brachial access positions. A table skirt cut lower body dose about fivefold; ceiling shields showed no measured effect here.

At a glance

Type of study
Original research, Dosimetry measurement study
Who was studied
Vascular surgeons, Trainees
Size
n = 415 dosimeter measurements
Summary based on
the abstract

What it found

  • Fenestrated endovascular aneurysm repair (EVAR) produced higher mean operator effective dose than other case types.

    Key figures: 20 μSv at position A, 9 μSv at position B; P < .03

  • Main operator position and the brachial access position received higher doses than more distant assistant positions.

    Key figures: A 9.0 μSv, D 20 μSv vs B 4 μSv, C 0.4 μSv; P < .001

  • A table lead skirt reduced lower body dose but not upper body dose.

    Key figures: lower body 33 ± 3.4 μSv to 6.3 ± 3.3 μSv; upper body 6.5 ± 3.3 μSv to 5.7 ± 2.2 μSv

  • Ceiling-mounted shielding and fellow training level did not affect operator dose in this study.

  • Authors estimate the primary operator could perform about 12 fenestrated endovascular aneurysm repairs (FEVARs) per week with annual dose under 10 mSv.

    Key figures: ~12 FEVARs/wk; <10 mSv/year

Limits to keep in mind

Single-center dosimetry with modest case numbers per procedure type and dosimeters at only two body sites outside the apron; no measurement of eye, hand or head dose, and the null ceiling-shield result may reflect positioning or use not reported.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.